Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients
Locations
United States
Florida
Mayo Clinic Cancer Center
RECRUITING
Jacksonville
Wisconsin
Medical College of Wisconsin
RECRUITING
Milwaukee
Contact Information
Primary
Arielle Baim
abaim@mcw.edu
4148058745
Time Frame
Start Date: 2025-08-28
Estimated Completion Date: 2029-05-14
Participants
Target number of participants: 200
Treatments
Patients who received Blinatumomab Therapy
Patients who did not receive Blinatumomab Therapy
Related Therapeutic Areas
Sponsors
Leads: Medical College of Wisconsin